MétaCan
Menu
Back to cohort

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma

2025· article· en· W4417256274 on OpenAlexaffabout
Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar, Ashlee Joseph, Taylor Brooks, Brian T. Hill, David A. Bond, Kami J. Maddocks, Imran Nizamuddin, Brad S. Kahl, Alexey V. Danilov, Christine Argao, Jia Ruan, Christine E. Ryan, Reid W. Merryman, Natalie S. Grover, Nazneen B. Khan, Aung M. Tun, Sabarish Ayyappan, Eric Mou, Georgios Pongas, Izidore S. Lossos, Zoey I. Harris, Javier Muñoz, Philip Young, Craig A. Portell, Firas Baidoun, Muhamad Alhaj Moustafa, Patrick M. Reagan, Lauren Banaszak, Priyanka A. Pophali, Arash Velayati, Irl Brian Greenwell, Drew G. Gerber, Preetesh Jain, Michael Wang, Mayur Narkhede, Amitkumar Mehta, Anthony Stack, Marcus Messmer, Rahul S. Bhansali, Stefan K. Barta, Tamara K. Moyo, Nilanjan Ghosh, Manali Kamdar, Alexander Stanisic, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsUniversity of British ColumbiaSpinal Cord Injury BCBC Cancer Agency
FundersPharmacyclicsGenentechIncyteIpsenBeiGeneRegeneron PharmaceuticalsSeagenGilead SciencesLoxo OncologyTG TherapeuticsPfizerMorphoSysCelgeneAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsRituximabMantle cell lymphomaRetrospective cohort studyLymphomaMaintenance therapyClinical trialOverall survival

Abstract

fetched live from OpenAlex

ABSTRACT: The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.067
Threshold uncertainty score0.698

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.002
GPT teacher head0.205
Teacher spread0.202 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicLymphoma Diagnosis and TreatmentFrench-language works237,207